Meeting Banner
Abstract #2165

Gadoxetate contrast kinetics are altered in rat liver by a peptide deformylase inhibitor known to induce phospholipidosis

Stephen Clark Lenhard 1 , Mary Rambo 2 , Ciara Rodgers 2 , Mark Burgert 2 , Lindsey Webster 3 , Richard Peterson 3 , Richard Miller 3 , and Beat Jucker 2

1 GlaxoSmithKline, King of Prussia, PA, United States, 2 GlaxoSmithKline, PA, United States, 3 GlaxoSmithKline, NC, United States

Phospholipidosis (PLD) is a generalized condition in humans and animals characterized by an intracellular accumulation of phospholipids. Using a clinically available liver specific MRI contrast agent (Eovist;Gadoxetate), hepatobiliary Dynamic Contrast Enhanced MRI (DCE-MRI) was performed to determine if Gadoxetate kinetic changes could be detected with a compound known to induce PLD. Gadoxetate DCE MRI of liver function may be a useful pre-clinical technique to assess hepatic functional consequences of PLD in vivo to support drug development decisions for compounds found to induce PLD.

This abstract and the presentation materials are available to members only; a login is required.

Join Here